Is reslizumab FDA approved?
The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older.
How much does reslizumab cost?
Table 5CDR Cost-Comparison Table for Treatments for Severe Eosinophilic Asthma
| Drug/Comparator | Strength | Price/Dose ($) |
|---|---|---|
| Reslizumab (Cinqair) | 10 mg/mL | 640.00 to 2,560.00b |
| Mepolizumab (Nucala) | 100 mg/mL | 1,938.46 |
| Other biologics indicated for a similar population | ||
| Omalizumab (Xolair) | 150 mg | 624.24 to 1,872.72 |
Who manufactures Cinqair?
Teva Respiratory, LLC, the manufacturer of Cinqair, offers Teva Support Solutions. For more information and to find out if you’re eligible for support, call 844-838-2211 or visit the program website.
How is reslizumab given?
Reslizumab comes as a solution (liquid) that is given intravenously (into a vein) by a doctor or nurse in a healthcare setting. It is usually given once every 4 weeks. It will take about 20 to 50 minutes for you to receive your dose of reslizumab.
How is Benralizumab made?
Benralizumab is a humanized monoclonal antibody (IgG1/κ-class) selective for interleukin-5 receptor alpha subunit (IL- 5Rα). Benralizumab is produced in Chinese hamster ovary cells by recombinant DNA technology. Benralizumab has a molecular weight of approximately 150 kDa.
What is Cinqair used for?
Cinqair (reslizumab) is an intravenous (IV) infusion given by a healthcare provider to treat severe asthma in adults when other medications aren’t working well enough. It’s not meant for use during asthma attacks.
Is Reslizumab an immunotherapy?
Reslizumab in the treatment of severe eosinophilic asthma: an update | Immunotherapy.
What is bronchial thermoplasty procedure?
Bronchial thermoplasty is an asthma treatment that targets the smooth muscle in the lungs. The treatment uses heat to shrink the smooth muscle so it can’t tighten and cause asthma symptoms. The treatment involves three sessions, with three weeks between each session.
How do you administer benralizumab?
The recommended dose of benralizumab is 30 mg by subcutaneous injection every 4 weeks for the first 3 doses, and then every 8 weeks thereafter. If an injection is missed on the planned date, dosing should resume as soon as possible on the indicated regimen; a double dose must not be administered.
What is reslizumab?
Reslizumab is a humanized monoclonal antibody that occupies the region ERRR (glutamic acid, arginine, arginine, arginine) corresponding to amino acids 89–92 on IL-5, which is a region critical for its interaction with the IL-5 receptor on the eosinophil surface 1.
What is reslizumab (Cinqair)?
Approved by the FDA in March 2016, reslizumab is marketed under the brand name Cinqair for intravenous injection. It is injected once every four weeks via intravenous infusion. Cinqair is indicated as an add-on maintenance therapy for adults with severe asthma with an eosinophilic phenotype.
How many mg of reslizumab can you take?
Single doses of up to 732 mg have been administered intravenously to subjects in clinical trials without evidence of dose-related toxicities. There is no specific treatment for an overdose with reslizumab. If the event of an overdose, the patient should be treated supportively with appropriate monitoring as necessary Label.
How long does reslizumab stay in your system?
As reslizumab bind to the target, it is not expected to undergo a target-mediated clearance Label. The half-life is approximately 24 days Label. Reslizumab clearance was approximately 7 mL/hour Label. With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.